DKSH brings Ubiquitome’s handheld COVID-19 test device to South East Asia, Australia and New Zealand May 15, 2020


			
				DKSH brings Ubiquitome’s handheld COVID-19 test device to South East Asia, Australia and New Zealand

DKSH and Ubiquitome have signed an exclusive agreement in South East Asia, Australia and New Zealand to introduce Liberty16, a handheld, battery-powered, real-time polymerase chain reaction (PCR) device that can fast test and relay sample data via an iPhone app within 40 minutes. 

Media release

DKSH brings Ubiquitome’s handheld COVID-19 test device to South East Asia, Australia and New Zealand

DKSH and Ubiquitome have signed an exclusive agreement in South East Asia, Australia and New Zealand to introduce Liberty16, a handheld, battery-powered, real-time polymerase chain reaction (PCR) device that can fast test and relay sample data via an iPhone app within 40 minutes. 

Singapore, May 15, 2020 – DKSH Business Unit Technology, a leading Market Expansion Services provider for technology companies seeking to grow their business in Asia, has entered into an exclusive partnership with Ubiquitome. Headquartered in Auckland, New Zealand, the company is attracting global inquiries due to its ability to deliver fast test results for COVID-19. DKSH will provide marketing and sales, distribution and logistics as well as after-sales services in Australia, Malaysia, New Zealand, Philippines, Singapore, Thailand and Vietnam. DKSH will also seek regulatory approval in each of the markets for the use of the solution to combat COVID-19.


Ubiquitome is a global leader in mobile genetic analysis devices. Their products offer gold standard real-time PCR performance, wherever needed. The company is seeking to revolutionize genetic analysis by creating universal access to genomic information through ubiquitous, cloud-connected, genetic analysis devices.


Liberty16 is a handheld, battery-powered, real-time PCR device that is able to run sixteen tests simultaneously and relay sample data via an iPhone app, all potentially within 40 minutes. It is a miniature DNA photocopier that can amplify specific target DNA sequences to show the presence of any DNA of interest, whether that be human, animal or wider environmental pathogens.


Paul Pickering, CEO, Ubiquitome stated: “The result of trials in the UK and Germany as well as the benefits of fast tracking prove that Liberty16 works and can greatly help during our battle against COVID-19. We are glad to partner with DKSH, a company with unparalleled market coverage in the APAC region. With this partnership, we believe more countries can start take advantage of this device.”


Hanno Elbraechter, Head Business Unit Technology, DKSH commented: “Developing our life science business and providing more innovative solutions for our business partners is a strategic focus of Business Unit Technology. We are glad to partner with Ubiquitome, a leading innovator in PCR technology. Ubiquitome’s solutions can be applied in various industries, such as clinical diagnostics, food & beverage and life science research. We look forward to successfully growing the business with Ubiquitome in the APAC region.”